MedTrace Logo

The Prevstain Trial

NCT04203043 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 338

Last updated 2020-02-07

No results posted yet for this study

Summary

To evaluate whether oral supplementation with Pycnogenol (Flebon®) can interfere with skin hyperpigmentation after polidocanol foam sclerotherapy in patients with mild to moderate chronic venous insufficiency (CEAP C2 and C3) compared with the use of Placebo.

Conditions

  • Varicose Veins

Interventions

DRUG

Pycnogenol Oral Product

pycnogenol use to prevent hyper pigmentation after foam sclerotherapy

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • University of Sao Paulo General Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-28
Primary Completion
2020-03-28
Completion
2021-12-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04203043 on ClinicalTrials.gov